34461-00-2

Basic information

• Product Name: NITROMALONALDEHYDE SODIUM
• Synonyms: NITROMALONALDEHYDE SODIUM;NITROMALONALDEHYDE SODIUM SALT;SODIUM NITROMALONALDEHYDE MONOHYDRATE;(1-Formyl-1-nitro-2-oxoethyl) monohydrate sodium, 3-Hydroxy-2-nitro-2-propenal monohydrate sodium salt, 3-Hydroxy-2-nitroacrolein monohydrate sodium salt, Sodium nitromalondialdehyde monohydrate, Sodium nitromalonic dialdehyde monohydrate, Sodium nitropropanedial monohydrate;Sodium nitromalonaldehyde;Nsc191937;Sodium nitromalonaldehyde monohydrate ,97%;SodiuM nitroMalondialdehyde Monohydrate
• CAS NO: 34461-00-2
• Molecular Formula: C₃H₂NNaO₄
• Molecular Weight: 139.04
• Mol File: 34461-00-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 120-124 °C
• Boiling Point: 15.6°C
• Flash Point: 126.1°C
• Appearance: /
• Vapor Pressure: 0.00222mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: NITROMALONALDEHYDE SODIUM(CAS DataBase Reference)
• NIST Chemistry Reference: NITROMALONALDEHYDE SODIUM(34461-00-2)
• EPA Substance Registry System: NITROMALONALDEHYDE SODIUM(34461-00-2)

Safety Data

• Hazard Codes: F,C
• Statements: 11-14-18-19-20/21/22-34
• Safety Statements: 16-26-33-36/37/39-45
• WGK Germany: 3
• Hazardous Substances Data: 34461-00-2(Hazardous Substances Data)

Usage

Uses

Sodium Nitropropanedial is used in preparation of phenylpyrrolopyridinylheteroarylcarboxamide derivatives. and analogs for use as c-kit protein kinases or mutant c-kit protein kinases modulators.

InChI:InChI=1/C3H3NO4/c5-1-3(2-6)4(7)8/h1-2,5H/p-1

Upstream product

• 488-11-9 mucobromic acid 
• 21577-50-4 mucobromic acid 
• 90994-06-2 (2E)-2,3-dibromo-4-oxobut-2-enoic acid 
• 7632-00-0 sodium nitrite 
• 766-38-1 mucobromic acid 

Downstream Products

• 1576-14-3 2,6-Diisopropyl-4-nitrophenol 
• 102703-36-6 4-Nitro-2,6-dioctyl-phenol 
• 14080-34-3 2-methyl-5-nitropyrimidine 
• 324-98-1 2-(4-fluorophenyl)-5-nitropyrimidine 
• 344312-90-9 2-(p-bromophenyl)-5-nitropyrimidine 
• 40824-92-8 2-nitro-3-(4-nitro-anilino)-acrylaldehyde 
• 34105-70-9 2-Ethyl-4-nitrophenol 
• 32345-10-1 (2-hydroxy-5-nitro-phenyl)-acetone 
• 100143-67-7 4-(2-nitro-3-oxo-propenylamino)-benzoic acid ethyl ester 
• 72078-90-1 2-Hydroxy-5-nitroisophthalsaeure-diethylester 
• 6563-64-0 ethyl 5-nitrofuro[2,3-b]pyridine-2-carboxylate 
• 14103-28-7 4-Nitro-2-phytyl-phenol 
• 98157-52-9 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
• 88848-40-2 1,3-bis(1-methyl-2-phenylindol-3-yl)-2-nitro-3-hydroxy-1-propene 

Relevant articles and documents

BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS

The present application relates to novel bicyclic compounds, to compositions comprising these compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3,4-B] PYRIDINE AND PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson?s disease, Alzheimer?s disease, Down?s Syndrome, Huntington?s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated there with using compounds and pharmaceutical compositions including the compounds.